Resources
5 Results (showing 1 - 5)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 10/23/2020 (updated 4/3/2024)
The American Society of Addiction Medicine (ASAM) developed this National Practice Guideline for the Treatment of Opioid Use Disorder to provide information on evidence-based treatment of opioid use disorder.
Posted 12/9/2020 (updated 4/3/2024)
Detailed risk benefit assessment of medications, settings and patient outcomes. These guidelines were developed in response to a resolution from the United Nations Economic and Social Council (ECOSOC), “to develop and publish minimum requirements and international guidelines on psychosocially assisted pharmacological treatment of persons dependent on opioids”
Posted 11/17/2021 (updated 4/3/2024)
Opioid use disorder (OUD) is a public health crisis affecting women, men, children, and society.1 Women with OUD have unique care needs and require a broad range of medical, behavioral health, and social services to meet these needs. Care coordination is important to manage the array of services that might be delivered to women in different settings. Without care coordination, women with OUD might struggle to access the services they need to get treatment and maintain recovery.
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders